Tallac Therapeutics is a Burlingame, California–based company developing multiple novel immunotherapies for solid tumors. Its Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform enables systemic delivery of differentiated TLR9 agonists to activate a specific anti-cancer immune response. TAC-001 is the company’s lead clinical candidate and is currently in an ongoing Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Tallac recently received a $15M venture loan facility from Horizon Technology Finance Corporation, of which $5M has been initially funded. The company will use the loan proceeds for general growth and working capital purposes. Tallac is led by president, CEO and co-founder Hong I. Wan, Ph.D., and is backed by investors including venBio, Lightstone Ventures, Morningside and MRL Ventures Fund. Tallac Therapeutics develops immunotherapies that harness both innate and adaptive immunity to fight cancer using its Toll‑like Receptor Agonist Antibody Conjugate (TRAAC) platform. The TRAAC platform delivers a potent TLR9 agonist (T‑CpG) via antibody conjugates to achieve targeted systemic immune activation. Several TRAAC molecules are in various stages of discovery and preclinical development. Tallac plans to use new funding to advance discovery and development of immunotherapy candidates across multiple solid tumor malignancies. The company emphasizes targeting innate immunity to generate more robust and durable anti‑tumor responses and to overcome resistance to checkpoint inhibitors and CAR‑T therapies. Tallac was founded in 2018 and is based in Burlingame, California, and is led by president and CEO Dr. Hong I. Wan.

Total raised

$77M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Aug 2023